Minerva Neurosciences, Inc. (NERV)
NCM · Healthcare · Biotechnology
$4.15
-0.24%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$198.2M
Shares Outstanding
47.7M
Exchange
NCM
Currency
USD
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.8M) | (5.0M) | (16.7M) | (10.6M) |
| Net Income | (2.7M) | (283.7M) | (125.4M) | 17.5M |
| Diluted EPS | $-0.36 | $-25.51 | $-2.86 | $-0.14 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (25.2M) | (23.1M) | (21.8M) | (15.1M) |
| Net Income | (32.1M) | (30.0M) | 1.4M | (293.4M) |
| Diluted EPS | $-6.01 | $-4.61 | $0.19 | $-34.67 |